The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Interesting tweet/X out last night from Netscientific.
Charles Swindell is presenting at the Jefferies Health Care on June 4-6th, talking about Glycotest and ProAxis.
He runs Glycotest and he hasn't said or done anything for at least 5 years.
Is it safe to assume we will have some positive Glycotest news beforehand otherwise he won't have much to say other than talk about 4 years of delays!?
I think the risk/reward is as good as it gets.
Glycotest is valued in the books at £11M and we are finally close to a read out. Could be worth £5M or £50M if the test works and Fosan want full control.
ProAxis worth £8M. since then received another £500K in funding grants. Might go for £10M/£15M with a fair wind.
Downside fully protected but upside is potentially massive.
That's great but as Saigonsally alluded , I'll be in my pine box by the time us shareholders make any decent return on this share!!!!
Need to start seeing some hardcore revenue's and profit on these investments.
NetScientific Q&A: "we're right in the middle of the action of venture capital"
https://youtu.be/6IqUrxEFql4
Much better than yesterdays Proactive interview. a win win for NSCI shareholders.
That's all very well and a great RNS today but it sounds to me like the cherry on the jam on the cream of our scone a very long way down the line. How do we squeeze a little bit more market appreciation out of what we have. We won't all live another 40 years (although maybe thanks to NSCI we shall...?).
ProAxis got another £500K grant on Friday.
More good news today being totally ignored by the wider market.
Perhaps some focus on our own share price before we go chasing other investments?
SP 60p vs NAV £2.00+. Just saying!!
Looking at IP GROUP discount to NAV.
They have gone down the share buy back route which is 100% where NSCI should be looking to close the gap between the 60p SP and the £2.00 NAV.
Why invest money elsewhere when you can effectively buy assets at a 200% discount!
Continued commitment to shareholder returns
- Launched further £20m share buyback fulfilling our commitment to regular cash returns from realisations
- As announced on 18 December 2023, future cash returns are expected to be in the form of share buybacks when the share price discount to NAV exceeds 20%
Totally agree Biffa. The problem for me (and a lot more, I suspect) is that even if the share price doubles I am still under water. And I am 'buttered' if I am going to stick in another penny while the shares are behaving like they do
Very bullish EMV First qtr newsletter just out.
Well worth a read.
Still can't quite believe we have only gained 1p on that news.
If they are going to sell the lot this summer for £10M in cash? then I hope they put a share buy back into the mix post results.
About time they started narrowing the discount of the 60p share price to the £2.00 asset value.
Nsci is delivering stunning capital growth as the exit some of these investments I am sure we will see elements of Capital distributions. They gave some heavy hitters in their portfolio insane that you can buy at below a third of NAV
This is a brilliant long term investment. Buy them under 60 and forget them. One day it will cash in one of these stakes for 50 times what it cost
Nsci’s biggest problem is that the only way to really deliver tangible returns for shareholders is via capital growth. That’s only going to come from a huge revaluation of its assets, so that the disconnect between its current mkt cap and its underlying NAV, becomes so huge that there’s no choice but for it to be recognised in an increased share price, or through the sale of one or more of its investments and a return of cash to shareholders as a special dividend, or through a floatation of same with Nsci shareholders being granted shares in a new company at the time of spin out.
It’s just not properly understood by the investor landscape yet, and the mgt team don’t seem that bothered to do anything to really sell NSCI to a wider audience …
Very frustrating
L.
There is only new money of 550k - the rest is conversions so its a tad misleading
Couldn't agree more.
Mr. Market is clearly in need of a double dose of Fluoxitine.
That is one fooking brilliant RNS.
Fair value up from £3.5M to £8M+
That is almost a third of todays Market Cap FFS!
Well done to the NSCI team.
If the market was actually working we would be +15/20p today.
Mark it down on shtt trades and ignore a decent 25k buy.
Modest increase on last years fair value of £41.8M (Dec 22) so lets say £45M or £1.80 a share.
MCap at 60p is £15M
Complete joke.
Start a buy back or make us a decent offer.
Almost all of their investments are finally on the up.
Not performing well - talk of raise required on Stockwits. £5m value atm puts a tad of pressure on the mcap given the permanent NAV disconnect. On my watchlist atm
Ventive 11%, EMV 25%
From Pipehawk half year 27/03/2024. They are one of the production partners for the new heat pump.
Recruitment has been a challenge as we have increased our staff levels to support the pending build profile of the contract manufacturing solutions. Inflation and cost of living increases have resulted in increased salary demands across the business. We have seen an increase of staff from 55 to 75 with more resource being required to support the contract manufacturing aspect of the business for both Caudwell Marine and Ventive, as well as considerations for Fast MDX, moving in to the latter stages of 2024. Commencement of contract manufacturing has suffered delays for the above reasons, but is moving ever closer. Caudwell is targeting start of production in July this year which will generate additional revenue towards the latter stages of 2024. In addition, Ventive has production targets on a similar timeframe.
QBot 15%, EMV 32%
USA and Europe.
Q-Bot, the UK construction tech company that uses robotics and AI to insulate people’s homes, has strengthened its Board with the appointment of a new Executive Chair and a second Investment Director.
Victor Vadaneaux has been appointed Executive Chair of Q-Bot. Victor has worked within B2B services, the engineering industry and the healthcare sector, and has extensive business and private equity experience of the UK, EU and US markets, including several successful exits.
Malcolm Groat has been appointed an Investment Director of Q-Bot, to work alongside Dr Ilian Iliev, the company’s existing Investment Director. Malcolm has more than 25 years of experience as a Chair, NED, CFO, and CEO in the public and private markets.
These senior board appointments significantly enhance Q-Bot’s capabilities and take place at an exciting time for the company and the construction industry. Using AI and robotics, Q-Bot’s insulation is deployed beneath suspended timber floors or to the underside of suspended concrete floors. In the UK alone, Q-Bot’s high performance retrofit insulation can help insulate the 8 to 12 million homes that have suspended floors and which are hard to treat using traditional forms of insulation. In the UK, Q-Bot’s customers include social housing landlords, energy companies and private homeowners. Internationally, the company has identified a further multi-billion market for robotics-based retrofit of insulation to residential homes in North America and North West Europe.
Victor and Malcolm will help Q-Bot to scale its robotics-as-a-service sales in the UK and expand its digital retrofit service. As its next phase of growth, Q-Bot is set to launch in the US and scale in the EU through strategic partnerships.
Their appointments have been facilitated by EMV Capital, a key investor in Q-Bot, and the company continues to draw on the value creation services provided by EMV Capital.
Have now launched SageTech Veterinary with a massive partnership.
At SageTech Veterinary, we are committed to eliminating waste, pollution and unnecessary environmental harm caused by volatile anaesthetic agents.
Our mission is to provide veterinary clinics with a safe, sustainable and easy to use solution for the capture, recovery and recycling of these agents, to lower their carbon footprint, and help to protect the planet for future generations.
SageTech Veterinary - Leading Sustainable Anaesthesia.
Find out more at www.sagetechveterinary.com
We are delighted to share our portfolio company SageTech Medical, the sustainable anaesthesia provider, has announced a partnership with Mars Veterinary Health and its UK veterinary clinic group Linnaeus.
A veterinary-industry first, Mars Veterinary Health’s one-year pilot will start with 10 Linnaeus primary care and referral veterinary practices in the UK with the aim of reducing anaesthesia-related carbon emissions resulting from release or disposal of these agents and determining the efficiency of capture in its clinics, ultimately supporting its goal of reducing climate-change impacts.
SageTech on a roll. We hold 5.5%, EMV 32%.
Recently SageTech Medical delivered 10 SID-Dock waste volatile anaesthetic gas capture machines to Cromwell Hospital.
Another successful delivery and installation for SageTech Medical!
We are pleased to announce that last week we installed our SID-Dock waste volatile anaesthetic gas capture machine at Benenden Hospital!
Benenden are helping to lead the way in delivering sustainable anaesthesia and are the first independent private hospital to adopt our technology!
Our SID-Dock waste volatile anaesthetic gas capture machine was recently installed at Castle Hill Hospital in Hull!
Our SID-Dock waste volatile anaesthetic gas capture machine was recently installed at Crosshouse Hospital in Scotland!
March Portfolio & Investment News
As we approach the end of an eventful Q1, the EMV Capital and NetScientific PLC Group is pleased to share the latest highlights across its deep tech and life sciences portfolio:
➡ Q-Bot Ltd has strengthened its Board with the appointment of Malcolm Groat as its second Investment Director, and a new Executive Chair to be announced shortly.
➡ ProAxsis has appointed EMV Capital and an external adviser to explore options for a potential sale of the company to a new strategic owner to scale the business to its full potential.
➡ SageTech Medical SID-Dock waste volatile anaesthetic gas capture machine was recently installed at NHS Ayrshire & Arran University Hospital Crosshouse and Hull University Teaching Hospitals NHS Trust Castle Hill Hospital. The company is now concentrating on the veterinary market, which represents a significantly higher emissions footprint compared to hospitals.
➡ Vortex Biosciences is focused on generating tightly scoped studies with leading researchers to highlight evidence of the technology to pharma and biotech customers.
➡ PDS Biotechnology has reported its 2023 financial results and outlined its clinical development strategy, which includes Phase 3 plans to address the growing incidence of advanced HPV+ HNSCC after FDA guidance.
➡ Ventive Limited and Q-Bot Ltd exhibited at the Futurebuild 2024 conference, where they showcased their innovative built environment solutions.
👇 Subscribe to our newsletter for more insights and updates: https://lnkd.in/etxzjW6J
Most impressed by the 2 presentations today.
So much going on it's difficult to keep up.
Pretty sure this will be moving a lot higher over the next few months.